#BEGIN_DRUGCARD DB00428

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01AD04

# Absorption:
Poor oral absorption (17-25%)

# Biotransformation:
Primarily hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
STREPTOZOTOCIN
STRZ
Streptozocin [Usan:Inn]
Streptozocine [INN-French]
Streptozocinium [Latin]
Streptozocinum [INN-Latin]
Zanosar

# CAS_Registry_Number:
18883-66-4

# ChEBI_ID:
9288

# Chemical_Formula:
C8H15N3O7

# Chemical_IUPAC_Name:
3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
622141

# Description:
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. [PubChem]

# Dosage_Forms:
Powder, for solution	Intravenous

# Drug_Category:
Antibiotics
Antibiotics, Antineoplastic
Antineoplastic Agents

# Drug_Interactions:
Bendamustine	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
11459269	Brentjens R, Saltz L: Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001 Jun;81(3):527-42.
13841501	VAVRA JJ, DEBOER C, DIETZ A, HANKA LJ, SOKOLSKI WT: Streptozotocin, a new antibacterial antibiotic. Antibiot Annu. 1959-1960;7:230-5.
4170654	Mansford KR, Opie L: Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968 Mar 30;1(7544):670-1.
7926307	Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33.
9421374	Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.45

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
5070 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Streptozocin

# HET_ID:
Not Available

# Half_Life:
5-15 minutes

# InChI_Identifier:
InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1

# InChI_Key:
InChIKey=ZSJLQEPLLKMAKR-GKHCUFPYSA-N

# Indication:
For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D05932

# LIMS_Drug_ID:
428

# Mechanism_Of_Action:
Although its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular structures including nucleic acids. Its cytotoxic action is probably due to cross-linking of strands of DNA, resulting in inhibition of DNA synthesis.

# Melting_Point:
115 Â°C

# Molecular_Weight_Avg:
265.2206

# Molecular_Weight_Mono:
265.090999849

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451514

# Pharmacology:
Streptozocin is an antitumour antibiotic consisting of a nitrosourea moiety interposed between a methyl group and a glucosamine. Streptozocin is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Streptozocin inhibits DNA synthesis in bacterial and mammalian cells. In bacterial cells, a specific interaction with cytosine moieties leads to degradation of DNA. The biochemical mechanism leading to mammalian cell death has not been definitely established; streptozocin inhibits cell proliferation at a considerably lower level than that needed to inhibit precursor incorporation into DNA or to inhibit several of the enzymes involved in DNA synthesis. Although streptozocin inhibits the progression of cells into mitosis, no specific phase of the cell cycle is particularly sensitive to its lethal effects.

# Predicted_LogP_Hydrophobicity:
-1.7

# Predicted_LogS:
-0.9

# Predicted_Water_Solubility:
3.35e+01 g/l

# Primary_Accession_No:
DB00428

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
29327

# PubChem_Substance_ID:
46508872

# RxList_Link:
http://www.rxlist.com/cgi/generic/zanosar.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00209

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.

# Update_Date:
2013-02-08 16:19:20 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Streptozocin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_1_ID:
4200

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_2_ID:
6013

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P05181

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP1A1

# Phase_1_Metabolizing_Enzyme_3_ID:
6024

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 1A1

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P04798

# Drug_Target_1_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
6454479	Bennett RA, Pegg AE: Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 1981 Jul;41(7):2786-90.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_1_General_Function:
Biological information storage and information transfer

# Drug_Target_1_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
874

# Drug_Target_1_Locus:
All loci

# Drug_Target_1_Molecular_Weight:
7656 (double strand)

# Drug_Target_1_Name:
DNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1BNA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Deoxyribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
7926307	Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33.
9421374	Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SLC2A2

# Drug_Target_2_GenBank_ID_Gene:
J03810

# Drug_Target_2_GenBank_ID_Protein:
307125

# Drug_Target_2_GeneCard_ID:
SLC2A2

# Drug_Target_2_Gene_Name:
SLC2A2

# Drug_Target_2_Gene_Sequence:
>1575 bp
ATGACAGAAGATAAGGTCACTGGGACCCTGGTTTTCACTGTCATCACTGCTGTGCTGGGT
TCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGCACCTCAACAGGTAATAATATCT
CACTATAGACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTATCAACAACTATGTT
ATCAACAGTACAGATGAACTGCCCACAATCTCATACTCAATGAACCCAAAACCAACCCCT
TGGGCTGAGGAAGAGACTGTGGCAGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCT
GTATCCAGCTTTGCAGTTGGTGGAATGACTGCATCATTCTTTGGTGGGTGGCTTGGGGAC
ACACTTGGAAGAATCAAAGCCATGTTAGTAGCAAACATTCTGTCATTAGTTGGAGCTCTC
TTGATGGGGTTTTCAAAATTGGGACCATCTCATATACTTATAATTGCTGGAAGAAGCATA
TCAGGACTATATTGTGGGCTAATTTCAGGCCTGGTTCCTATGTATATCGGTGAAATTGCT
CCAACCGCTCTCAGGGGAGCACTTGGCACTTTTCATCAGCTGGCCATCGTCACGGGCATT
CTTATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAATTATGATCTGTGGCACATC
CTGCTTGGCCTGTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTTTTTCTGTCCA
GAAAGCCCCAGATACCTTTACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAAGCTTG
AAAAGACTCAGAGGATATGATGATGTCACCAAAGATATTAATGAAATGAGAAAAGAAAGA
GAAGAAGCATCGAGTGAGCAGAAAGTCTCTATAATTCAGCTCTTCACCAATTCCAGCTAC
CGACAGCCTATTCTAGTGGCACTGATGCTGCATGTGGCTCAGCAATTTTCCGGAATCAAT
GGCATTTTTTACTACTCAACCAGCATTTTTCAGACGGCTGGTATCAGCAAACCTGTTTAT
GCAACCATTGGAGTTGGCGCTGTAAACATGGTTTTCACTGCTGTCTCTGTATTCCTTGTG
GAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAATGAGTGGGATGTTTGTTTGTGCC
ATCTTCATGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGATGAGTTATGTGAGC
ATGATAGCCATCTTCCTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATCCCCTGG
TTCATGGTGGCTGAGTTTTTCAGTCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCA
TTCAGCAATTGGACCTGCAATTTCATTGTAGCTCTGTGTTTCCAGTACATTGCGGACTTC
TGTGGACCTTATGTGTTTTTCCTCTTTGCTGGAGTGCTCCTGGCCTTTACCCTGTTCACA
TTTTTTAAAGTTCCAGAAACCAAAGGAAAGTCTTTTGAGGAAATTGCTGCAGAATTCCAA
AAGAAGAGTGGCTCAGCCCACAGGCCAAAAGCTGCTGTAGAAATGAAATTCCTAGGAGCT
ACAGAGACTGTGTAA

# Drug_Target_2_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_2_General_References:
10987651	Burwinkel B, Sanjad SA, Al-Sabban E, Al-Abbad A, Kilimann MW: A mutation in GLUT2, not in phosphorylase kinase subunits, in hepato-renal glycogenosis with Fanconi syndrome and low phosphorylase kinase activity. Hum Genet. 1999 Sep;105(3):240-3.
11044475	Sakamoto O, Ogawa E, Ohura T, Igarashi Y, Matsubara Y, Narisawa K, Iinuma K: Mutation analysis of the GLUT2 gene in patients with Fanconi-Bickel syndrome. Pediatr Res. 2000 Nov;48(5):586-9.
3399500	Fukumoto H, Seino S, Imura H, Seino Y, Eddy RL, Fukushima Y, Byers MG, Shows TB, Bell GI: Sequence, tissue distribution, and chromosomal localization of mRNA encoding a human glucose transporter-like protein. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5434-8.
8027028	Mueckler M, Kruse M, Strube M, Riggs AC, Chiu KC, Permutt MA: A mutation in the Glut2 glucose transporter gene of a diabetic patient abolishes transport activity. J Biol Chem. 1994 Jul 8;269(27):17765-7.
8063045	Tanizawa Y, Riggs AC, Chiu KC, Janssen RC, Bell DS, Go RP, Roseman JM, Acton RT, Permutt MA: Variability of the pancreatic islet beta cell/liver (GLUT 2) glucose transporter gene in NIDDM patients. Diabetologia. 1994 Apr;37(4):420-7.

# Drug_Target_2_HGNC_ID:
HGNC:11006

# Drug_Target_2_HPRD_ID:
00685

# Drug_Target_2_ID:
1638

# Drug_Target_2_Locus:
3q26.1-q26.2

# Drug_Target_2_Molecular_Weight:
57490

# Drug_Target_2_Name:
Solute carrier family 2, facilitated glucose transporter member 2

# Drug_Target_2_Number_of_Residues:
524

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Glibenclamide Pathway	SMP00460
Gliclazide Pathway	SMP00461
Nateglinide Pathway	SMP00453
Repaglinide Pathway	SMP00454

# Drug_Target_2_Pfam_Domain_Function:
PF00083	Sugar_tr

# Drug_Target_2_Protein_Sequence:
>Solute carrier family 2, facilitated glucose transporter member 2
MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYV
INSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGWLGD
TLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIA
PTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLFFCP
ESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTNSSY
RQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSVFLV
EKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGPIPW
FMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFTLFT
FFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Facilitative glucose transporter. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell. May also participate with the Na(+)/glucose cotransporter in the transcellular transport of glucose in the small intestine and kidney

# Drug_Target_2_SwissProt_ID:
P11168

# Drug_Target_2_SwissProt_Name:
GTR2_HUMAN

# Drug_Target_2_Synonyms:
Glucose transporter type 2, liver

# Drug_Target_2_Theoretical_pI:
8.10

# Drug_Target_2_Transmembrane_Regions:
11-31
99-119
128-148
159-179
188-208
218-238
304-324
339-359
369-389
401-421
434-454
462-482

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
19217614	He Y, Martinez-Fleites C, Bubb A, Gloster TM, Davies GJ: Structural insight into the mechanism of streptozotocin inhibition of O-GlcNAcase. Carbohydr Res. 2009 Mar 31;344(5):627-31. doi: 10.1016/j.carres.2008.12.007. Epub 2008 Dec 13.

# Drug_Target_3_Essentiality:
Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE015928

# Drug_Target_3_GenBank_ID_Protein:
29337303

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
BT_4395

# Drug_Target_3_Gene_Sequence:
>618 bp
TTGGTATCTACCAGTACGCACGACGATGCTTTTGACTTCGACTTTGGTTACACTGGTAAG
CTTCAGTTCTTGGTAGCCACTGTAGATGCAAATAGTACCTATTACACTAAAGACCCGAAT
GGTATTGAATGTGATAACGACGGAAGCAGTTCATCTTTAACTCCGTTCACTCACCCGACA
ATCAGTAACTTAACAATCGTTGGAACCGTTAATGGTAAGGTTGCACAATCTGCAATGGGT
GATGGTAAATCCATGAAATCTTGTGCCAACTTCCGTAGAAACTGCCAATTTACTTTGGTG
AACAGTATTCTTTACGGATATCCTACCGGTATCTTGTGTGAAACCACTAACAGCTATGTT
TTCAAAAACAATGTTGTAAATGGTGTTAGTACTACATTTTCAGGTATCACAGCTGACGCG
ACTAATACTGCTGCTGCAAGTGCTGAGGCTATTGGGCTGACTTCTCCGTGGGGTGGATAT
ACAGGTTTGATGCCTAATGCATCTCCAGCCAATGCAGGTGCAGATTTTAGTGAATTGGAT
AGTTGGTTTACGACTACTTCTTACAGAGGTGCTGTTGGTGGACGTTCAAACTGGTTAACT
CAAGCGTGGGTAAAATAA

# Drug_Target_3_General_Function:
Involved in beta-N-acetylhexosaminidase activity

# Drug_Target_3_General_References:
12663928	Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI: A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science. 2003 Mar 28;299(5615):2074-6.
16565725	Dennis RJ, Taylor EJ, Macauley MS, Stubbs KA, Turkenburg JP, Hart SJ, Black GN, Vocadlo DJ, Davies GJ: Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity. Nat Struct Mol Biol. 2006 Apr;13(4):365-71. Epub 2006 Mar 26.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6766

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
84484.6

# Drug_Target_3_Name:
O-GlcNAcase BT_4395

# Drug_Target_3_Number_of_Residues:
737

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF07555	Hyaluronidase_2

# Drug_Target_3_Protein_Sequence:
>O-GlcNAcase BT_4395
MKNNKIYLLGACLLCAVTTFAQNVSLQPPPQQLIVQNKTIDLPAVYQLNGGEEANPHAVK
VLKELLSGKQSSKKGMLISIGEKGDKSVRKYSRQIPDHKEGYYLSVNEKEIVLAGNDERG
TYYALQTFAQLLKDGKLPEVEIKDYPSVRYRGVVEGFYGTPWSHQARLSQLKFYGKNKMN
TYIYGPKDDPYHSAPNWRLPYPDKEAAQLQELVAVANENEVDFVWAIHPGQDIKWNKEDR
DLLLAKFEKMYQLGVRSFAVFFDDISGEGTNPQKQAELLNYIDEKFAQVKPDINQLVMCP
TEYNKSWSNPNGNYLTTLGDKLNPSIQIMWTGDRVISDITRDGISWINERIKRPAYIWWN
FPVSDYVRDHLLLGPVYGNDTTIAKEMSGFVTNPMEHAESSKIAIYSVASYAWNPAKYDT
WQTWKDAIRTILPSAAEELECFAMHNSDLGPNGHGYRREESMDIQPAAERFLKAFKEGKN
YDKADFETLQYTFERMKESADILLMNTENKPLIVEITPWVHQFKLTAEMGEEVLKMVEGR
NESYFLRKYNHVKALQQQMFYIDQTSNQNPYQPGVKTATRVIKPLIDRTFATVVKFFNQK
FNAHLDATTDYMPHKMISNVEQIKNLPLQVKANRVLISPANEVVKWAAGNSVEIELDAIY
PGENIQINFGKDAPCTWGRLEISTDGKEWKTVDLKQKESRLSAGLQKAPVKFVRFTNVSD
EEQQVYLRQFVLTIEKK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-21

# Drug_Target_3_Specific_Function:
Biological function unknown. Capable of hydrolyzing the glycosidic link of O-GlcNAcylated proteins

# Drug_Target_3_SwissProt_ID:
Q89ZI2

# Drug_Target_3_SwissProt_Name:
OGA_BACTN

# Drug_Target_3_Synonyms:
Beta-N-acetylhexosaminidase
Beta-hexosaminidase
GH84
Hexosaminidase B
N-acetyl-beta-glucosaminidase

# Drug_Target_3_Theoretical_pI:
7.00

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00428
